Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pumpkin seed pill shows promise for bladder control in small study

NCT ID NCT07571616

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a pumpkin seed supplement (NatureU Pelvic Health) in 19 women aged 35–55 with urinary frequency and leakage. Participants took two tablets daily for 7 days. Results showed improvements in toileting behavior and quality of life, but the study was small and had no placebo group, so more research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

19 people

The number who actually took part.

Started

Jul 2024

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 55 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent before the study and understood the study content, procedures, and possible adverse reactions. * Adult woman aged 35 to 55 years, inclusive. * Had urinary frequency and urinary leakage symptoms. * Body weight at least 50 kg. * Body mass index between 18.5 and 23.9 kg/m2, inclusive. * Able to maintain normal healthy routines during the study period. * Able to abstain from alcohol during the study period. Exclusion Criteria: * Pregnant or breastfeeding. * Recent pregnancy plans. * Known allergy or hypersensitivity to product ingredients, including pumpkin or soybean. * History of multiple food allergies. * Diagnosed diabetes or other metabolic disease. * Clinically significant abnormalities in blood glucose, blood pressure, physical examination, or vital signs as judged by the investigator. * Acute or chronic inflammatory disease, including influenza A, within the previous month. * Participation in any other clinical trial within 1 month before first use of the study product. * Clinically significant disease within the previous 6 months judged by the investigator to make participation inappropriate. * Acute illness or concomitant medication use from screening to first use of the study product. * Surgery within the previous 3 months. * Blood donation or major blood loss greater than 450 mL within the previous 3 months. * Difficulty swallowing. * Gastrointestinal disease history affecting product intake. * Any disease that increases bleeding risk, such as hemorrhoids, acute gastritis, or gastric or duodenal ulcer. * Use of prescription or non-prescription medications affecting nutritional supplements or hormone levels. * Substantial weight change within the previous month. * Any other factor judged by the investigator to make participation inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urinary frequency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Urinary Incontinence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dao County People's Hospital

    Yongzhou, Hunan, 425300, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.